Specific diagnostic criteria and structured diagnostic methods are not established in this packet's fields.

Three FDA-approved therapies for CIDP carry active market status in this packet. Immune Globulin (Human) — marketed as Baygam and Gamastan S/D — holds BLA approval and currently maintains active market status; the approval date recorded in this packet (January 11, 2044) is anomalous and appears to reflect a data entry artifact rather than the actual historical approval date for this product. Efgartigimod alfa and hyaluronidase-qvfc (VYVGART HYTRULO) received BLA approval on June 20, 2023, and is currently marketed with active status. Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase (Hyqvia) received BLA approval on September 12, 2014, and is currently marketed with active status.

Prognostic information is not established in this packet's structured fields.

Two clinical trials for CIDP are documented as recruiting in this packet. NCT06752356 is a Phase 3 study investigating intravenous immune globulin 10% KIg10 (QIVIGY) in subjects with CIDP, sponsored by Kedrion S.p.A., with planned initiation October 2026 and planned completion December 2027. NCT07032662 is a Phase 2 study of imeroprubart in adult participants with CIDP, sponsored by Immunovant Sciences GmbH, with enrollment begun March 2025 and planned completion May 2030.